Physician profile
Madhur Gupta
NPI 1588818298
$600.42
in general payments reported to CMS, 2019-2025
11 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $448 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $148.77 | 2024 | Airsupra, Farxiga |
| Novo Nordisk INC | $144.25 | 2024 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $90.62 | 2024-2025 | Eterna, Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $52.05 | 2024 | Zepbound, Mounjaro, Amyvid |
| Abbvie INC. | $39.97 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.66 | 2024 | Xifaxan |
| Axsome Therapeutics, INC. | $27.90 | 2025 | Auvelity |
| Irhythm Technologies, INC. | $21.72 | 2024 | Zio Xt Patch, Zio Monitor |
| Pfizer INC. | $15.68 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.49 | 2024 | Jardiance |
| Amgen INC. | $14.31 | 2025 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhur Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.